UniQure's AMT-130 Slows Huntington's Progression at Four Years, but Benefit Wanes Versus One-Year Analysis
核心洞察
UniQure reported that its one-time gene therapy AMT-130 continued to slow Huntington's disease (搜索) progression four years after surgical implantation into patients' brains.
A high dose of AMT-130 slowed disease progression by 44% versus matched external controls from a large natural history study, a difference that was not statistically significant.
The magnitude of benefit has waned compared with a similar analysis conducted one year earlier, raising questions about durability as the FDA reviews UniQure's marketing application.
UniQure's experimental gene therapy for Huntington's disease (搜索) continued to slow progression of the neurodegenerative disorder four years after it was surgically implanted into patients' brains, the company reported Tuesday. The one-time therapy, AMT-130, is now under review by the Food and Drug Administration (搜索), which has begun evaluating UniQure's marketing application.
In the new four-year analysis, a high dose of AMT-130 slowed the progression of Huntington's by 44% compared with matched participants in an external control group drawn from a large natural history study. The difference was not statistically significant.
Durability Question Emerges
The magnitude of the treatment's benefit has waned compared with a similar analysis conducted one year ago. That decline may raise questions about the durability of the therapy's effect at a point when regulators are already assessing the company's filing.
The findings rest on a comparison against external controls rather than a randomized concurrent placebo arm, and the absence of statistical significance in the four-year dataset leaves the strength of the signal open to interpretation. UniQure has not reported additional details from the analysis beyond the 44% slowing in the high-dose group and the comparison with the prior year's results.
Regulatory Timing
The four-year data arrive as the FDA reviews UniQure's marketing application for AMT-130, making the durability question central to the therapy's path forward. Huntington's disease (搜索) is a progressive, fatal neurodegenerative condition, and AMT-130 is delivered as a single surgical administration into the brain rather than through repeated dosing.